About Repros
Company Overview
Board of Directors and Management
Pipeline
Androxal
®
Male Fertility Maintenance/Improvement
Type II Diabetes
Publications
Proellex
®
Uterine Fibroids
Endometriosis
Publications
Clinical Trials
Investors & Media
Events, Presentations and Webcasts
Repros in the News
Analyst Coverage
SEC Filings
Corporate Governance
Contact Us
January 27, 2012
Repros Announces Registered Direct Offering of Approximately $11.1 Million
January 5, 2012
Repros to Present at Bioshowcase in San Francisco on 1/9/12 and Host Analyst Day in New York on 1/25/12
January 4, 2012
Repros' IND for Proellex®-V Accepted by the FDA
January 3, 2012
Repros Completes Dosing in Phase 2 Low-Dose Oral Proellex® Trial
There are no scheduled events.
"I've been on male birth control and didn't know it"
says one patient dealing with male infertility.
Terms of Use
© Repros Therapeutics Inc. All rights reserved.
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax
